OSTEOLOGIX COMPLETES ENROLLMENT FOR OSTEOPOROSIS TRIAL

Osteologix reported that it has completed patient enrollment in the first Phase I clinical trial of its novel compound NBS-101 to treat osteoporosis. NBS-101 is being studied as an improved formulation of strontium, which was recently approved in Europe, in the form of strontium ranelate, and launched in several European countries.

The objective of the initial NBS-101 human clinical trial is to establish a dose required to deliver the same blood levels of strontium as strontium ranelate, the recently approved European product. Preclinical studies suggest that a substantially lower dose of NBS-101 may deliver the same amount of active ingredient as the 2-gram dose used in the commercialized version currently available in European markets.